Thera-SAbDab

GUSELKUMAB

> Structural Summary

Therapeutic	Guselkumab
Target	IL23A
Heavy Chain	EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS
Light Chain	QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL
100% seqID Fv Structure	4m6m [Fvs: HL], 4m6n [Fvs: HL]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	4m6m [Fvs: HL]
100% seqID Structure	4m6n [Fvs: HL]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Approved
Estimated Status (June '19)	Active
Recorded Developmental Technology	MorphoSys HuCAL Phage Display
INN Year Proposed	2013
INN Year Recommended	2014
Companies Involved	Janssen Biotech, MorphoSys, Taiho Pharmaceutical
Conditions Approved	Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis
Conditions Active	Crohn's disease, Hidradenitis suppurativa, Rheumatoid arthritis, Ulcerative colitis, Familial adenomatous polyposis
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]